Pharsight

Daklinza is owned by Bristol-Myers Squibb.

Daklinza contains Daclatasvir Dihydrochloride.

Daklinza has a total of 5 drug patents out of which 0 drug patents have expired.

Daklinza was authorised for market use on 24 July, 2015.

Daklinza is available in tablet;oral dosage forms.

Daklinza can be used as method of inhibiting hepatitis c virus; method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity, method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity; method of inhibiting hepatitis c virus, method of inhibiting hepatitis c virus.

The generics of Daklinza are possible to be released after 13 June, 2031.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9421192	BRISTOL-MYERS SQUIBB	Hepatitis C virus inhibitors	Aug, 2027 (4 years from now)
US8642025	BRISTOL-MYERS SQUIBB	Hepatitis C virus inhibitors	Aug, 2027 (4 years from now)
US8329159	BRISTOL-MYERS SQUIBB	Hepatitis C virus inhibitors	Jul, 2029 (6 years from now)
US8629171	BRISTOL-MYERS SQUIBB	Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt	Jun, 2031 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8900566	BRISTOL-MYERS SQUIBB	Hepatitis C virus inhibitors	Aug, 2027 (4 years from now)

Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient

Market Authorisation Date: 24 July, 2015

Treatment: Method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity; Method of inhibiting hepatitis c virus

Dosage: TABLET;ORAL